Here's What Rahm Emanuel Said That Caused This Podcaster to Totally Melt Down
Why People Are Posting About JD Vance After Pope Francis Passed Away
FDA Announces Major 'Make America Healthy Again' Shakeup
Federal Court Shuts Down Trump's Effort to Dismantle 'Voice of America'
Trump’s Deportation Plan Hits Another Legal Roadblock, Thanks to This Federal Judge
Kaitlin Collins Is Undermined By Her Own Network, and '60 Minutes' Producer Quits...
Gun Control Group Hopes No One Will Remember Its Founder's Own Words
Trump Admin Arrests One of India’s Most-Wanted Fugitives Tied to Deadly Terror Attacks
Democrats Scramble to Criticize Trump White House Over Using Real Eggs at Easter...
'Beloved' GOP Texas Politician Stabbed, Husband Killed In Violent Attack
More of Dems in Disarray: Gavin Newsom Criticizes Party for Failing to Figure...
'60 Minutes' Producer Resigns Amid Trump Lawsuit Chaos and CBS Backlash
Rubio Announces Major Shakeup at State Department
Democrats Can Go to El Salvador on GOP Dime, on One Condition
Yet Another Poll Brings Catastrophic News for Democrats
Tipsheet

Operation Warp Speed Gets a Financial Boost

(AP Photo/Ted S. Warren, File)

The Trump administration has awarded $1.6 billion to Novavax, a biotechnology company based in Maryland, to develop, produce, and distribute a coronavirus vaccine. Novavax says it hopes to produce 100 million doses of the vaccine by late 2020.

Advertisement

“More good news about COVID-19 therapeutics is constantly emerging, and President Trump’s commitment to supporting lifesaving therapeutics will help deliver these products to American patients without a day’s delay,” said HHS Secretary Alex Azar in a statement.

“We are honored to partner with Operation Warp Speed to move our vaccine candidate forward with extraordinary urgency in the quest to provide vital protection to our nation’s population,” said Stanley C. Erck, President and Chief Executive Officer of Novavax.

Federal assistance will finance Phase 3 clinical trials for Novavax’s vaccine candidate and facilitate production in a newly-acquired facility in the Czech Republic. According to STAT, the company will also establish production sites in India and Asia. 

“I think that takes care of a lot of the issues around potential border closings, so that vaccine will be available for the globe,” Erck told STAT.

Novavax received $388 million from the Coalition for Epidemic Preparedness Innovations for Phase 1 and 2 clinical trials, with results expected later this month. A pre-published paper demonstrated the effectiveness of the vaccine in non-human subjects. The vaccine is administered in two doses, but the possibility exists for a single-dose inoculation. 

Advertisement

The grant functions as part of the federal government’s “Operation Warp Speed,” a collaboration between numerous federal agencies, including the CDC, NIH, and FDA, to expedite vaccine development and production. Public-private partnerships will ostensibly allow the research, development, and licensure processes to occur simultaneously rather than successively.  

“Operation Warp Speed is creating a portfolio of vaccines to increase the odds that we will have at least one safe, effective vaccine as soon as the end of this year,” said Sec. Azar.

Regeneron, a NY-based therapeutics developer, also received a $450 million grant today. Seven other companies, ranging from biotechnology to medical manufacturing, have received contracts from the federal government as part of Operation Warp Speed, and more are expected to participate. Congress announced nearly $10 billion in available funds for the operation.

Francis Collins, director of the NIH, explained the rationale behind Operation Warp Speed: “To put it really simply, drug development is a series of boxes you have to check—very complicated boxes, but boxes nonetheless…OWS requires checking each and every one of those boxes just like we would for any other project, but we aren’t going one by one down the list. We’re aiming to check as many of them simultaneously as we can.”

Advertisement

Responding to criticism about the operation’s alleged lack of transparency, Collins testified on July 2 that “we are strictly adhering to and following all required regulatory and safety requirements required for vaccine development. We are not sacrificing the safety of the vaccine in order to expedite its development.” 

He claimed the federal government would shoulder the investment risk. 

Join the conversation as a VIP Member

Recommended

Trending on Townhall Videos

Advertisement
Advertisement
Advertisement